Boston Scientific (NYSE:BSX) Given New $57.00 Price Target at UBS Group

Key Points

• UBS Group lowered Boston Scientific’s price target to $57 from $67 but maintained a “buy” rating, implying approximately 35.55% upside from the stock’s $42.05 price.
• Analyst sentiment remains mixed: Boston Scientific has an overall “Moderate Buy” rating and an average price target of $62.17, while JPMorgan downgraded the stock to “neutral” with a $46 target.
• The company matched quarterly EPS expectations at $0.73 and exceeded revenue estimates with $5.14 billion, but an eight-day cybersecurity outage reduced sales by roughly $150 million and led management to lower its outlook amid continued operational and market pressures.

Boston Scientific (NYSE:BSX - Get Free Report) had its price objective decreased by analysts at UBS Group from $67.00 to $57.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has a "buy" rating on the medical equipment provider's stock. UBS Group's price objective would indicate a potential upside of 35.55% from the stock's current price.

Several other equities analysts also recently issued reports on BSX. JPMorgan Chase & Co. downgraded shares of Boston Scientific from an "overweight" rating to a "neutral" rating and set a $46.00 price objective on the stock. in a report on Wednesday. Robert W. Baird boosted their target price on shares of Boston Scientific from $50.00 to $51.00 and gave the stock an "outperform" rating in a research note on Thursday. Wall Street Zen downgraded shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, August 2nd. Mizuho set a $50.00 price target on shares of Boston Scientific in a research report on Thursday. Finally, Leerink Partners set a $50.00 price target on shares of Boston Scientific in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Boston Scientific currently has an average rating of "Moderate Buy" and an average price target of $62.17.

Boston Scientific Price Performance

BSX traded down $0.38 during trading on Thursday, hitting $42.05. The company's stock had a trading volume of 18,487,376 shares, compared to its average volume of 18,669,098. The firm has a market capitalization of $60.94 billion, a price-to-earnings ratio of 17.01, a P/E/G ratio of 1.10 and a beta of 0.58. Boston Scientific has a twelve month low of $39.57 and a twelve month high of $105.65. The business's fifty day simple moving average is $45.12 and its 200 day simple moving average is $57.43. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The business had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.07 billion. During the same period in the prior year, the company posted $0.75 EPS. The business's quarterly revenue was up 1.4% on a year-over-year basis. On average, equities research analysts forecast that Boston Scientific will post 3.21 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director David Habiger purchased 2,100 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares of the company's stock, valued at $816,644.40. The trade was a 13.94% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Edward Ludwig acquired 5,000 shares of the company's stock in a transaction that occurred on Friday, July 31st. The shares were acquired at an average cost of $45.48 per share, with a total value of $227,400.00. Following the purchase, the director owned 30,359 shares in the company, valued at $1,380,727.32. This represents a 19.72% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have acquired 194,522 shares of company stock valued at $9,385,210. Corporate insiders own 0.34% of the company's stock.

Institutional Investors Weigh In On Boston Scientific

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank Julius Baer & Co. Ltd Zurich lifted its position in shares of Boston Scientific by 1.4% in the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 19,918 shares of the medical equipment provider's stock valued at $870,000 after acquiring an additional 268 shares in the last quarter. Heritage Investors Management Corp boosted its stake in shares of Boston Scientific by 8.0% during the third quarter. Heritage Investors Management Corp now owns 230,064 shares of the medical equipment provider's stock valued at $10,042,000 after acquiring an additional 17,107 shares during the last quarter. Greenleaf Trust increased its position in Boston Scientific by 3.9% during the 3rd quarter. Greenleaf Trust now owns 23,939 shares of the medical equipment provider's stock worth $1,045,000 after purchasing an additional 906 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Boston Scientific during the 3rd quarter worth about $17,463,000. Finally, Vise Technologies Inc. raised its stake in Boston Scientific by 22.6% in the 3rd quarter. Vise Technologies Inc. now owns 35,744 shares of the medical equipment provider's stock valued at $1,560,000 after purchasing an additional 6,585 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported third-quarter revenue of $5.138 billion, up approximately 1.5% year over year and above the $5.07 billion analyst estimate. Adjusted EPS of $0.73 matched consensus, while management highlighted continued long-term investment and new clinical and regulatory milestones. Boston Scientific announces results for third quarter 2026
• Positive Sentiment: Analyst views remain mixed rather than uniformly bearish. Robert W. Baird raised its price target to $51 and maintained an outperform rating, while BTIG kept a buy rating with a reduced $49 target. Recent insider purchases, including a sizable purchase by CEO Michael Mahoney, may also offer some support for investor sentiment.
• Neutral Sentiment: Several firms adjusted their expectations after the results. Wells Fargo lowered its target to $45 and retained an equal-weight rating; Needham cut its target to $48 but kept a buy rating; and JPMorgan downgraded the stock to neutral with a $46 target. Oppenheimer also moved from outperform to market perform. Analysts revise forecasts on Boston Scientific
• Negative Sentiment: An eight-day cybersecurity outage reduced third-quarter sales by roughly $150 million and continues to disrupt operations. Management lowered its full-year 2026 outlook to approximately 4.25% reported sales growth and expects fourth-quarter reported and organic sales to decline 1% to 3%. Fourth-quarter adjusted EPS guidance of $0.77 to $0.79 was below market expectations. Boston Scientific earnings and cybersecurity impact
• Negative Sentiment: Management warned that growth could remain challenging through 2027 because of cybersecurity-related rebuilding, weakness in electrophysiology and WATCHMAN heart-device sales, and pricing pressure in China. Contracting margins and lower EPS guidance have therefore outweighed the quarterly revenue beat, pressuring BSX shares.

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.